Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transcutaneous (Topical) Peptide Immunization With NY-ESO-1b (SLLMWITQC) Peptide Using Resiquimod as an Immune Adjuvant: A Pilot Study

NCT00470379 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00470379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00470379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transcutaneous (Topical) Peptide Immunization With NY-ESO-1b (SLLMWITQC) Peptide Using Resiquimod as an Immune Adjuvant: A Pilot Study
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2006
Completion date
October 31, 2011
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)